Bausch Health Companies (NYSE:BHC) PT Set at $28.00 by Barclays

Barclays set a $28.00 target price on Bausch Health Companies (NYSE:BHC) in a research report report published on Monday morning, Stock Target Advisor reports. The firm currently has a buy rating on the stock.

A number of other research analysts have also recently issued reports on the company. Cantor Fitzgerald set a $32.00 target price on Bausch Health Companies and gave the company a buy rating in a research report on Friday, May 31st. SunTrust Banks assumed coverage on Zoetis in a research report on Tuesday, March 19th. They issued a hold rating and a $100.00 target price on the stock. Piper Jaffray Companies set a $29.00 target price on Bausch Health Companies and gave the company a buy rating in a research report on Tuesday, June 11th. ValuEngine cut Virtu Financial from a hold rating to a sell rating in a research report on Tuesday, June 18th. Finally, Zacks Investment Research cut HENGAN INTL GRP/ADR from a strong-buy rating to a hold rating in a research report on Tuesday, May 21st. Three research analysts have rated the stock with a sell rating, four have assigned a hold rating and ten have issued a buy rating to the stock. Bausch Health Companies currently has an average rating of Hold and a consensus price target of $27.65.

Bausch Health Companies stock opened at $23.87 on Monday. Bausch Health Companies has a 12-month low of $17.20 and a 12-month high of $28.45. The company has a debt-to-equity ratio of 8.61, a quick ratio of 0.83 and a current ratio of 1.08. The company has a 50-day simple moving average of $23.17. The company has a market capitalization of $8.77 billion, a PE ratio of 5.99, a PEG ratio of 0.56 and a beta of 0.78.

Bausch Health Companies (NYSE:BHC) last released its earnings results on Monday, May 6th. The company reported $1.03 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.89 by $0.14. Bausch Health Companies had a positive return on equity of 47.01% and a negative net margin of 19.27%. The firm had revenue of $2.02 billion for the quarter, compared to analysts’ expectations of $2.03 billion. During the same quarter in the previous year, the business posted $0.89 earnings per share. The business’s revenue for the quarter was up 1.1% on a year-over-year basis. Research analysts forecast that Bausch Health Companies will post 4.19 earnings per share for the current year.

Large investors have recently added to or reduced their stakes in the company. Valeo Financial Advisors LLC lifted its stake in Bausch Health Companies by 40.8% in the second quarter. Valeo Financial Advisors LLC now owns 4,831 shares of the company’s stock valued at $122,000 after buying an additional 1,400 shares during the period. Sanders Morris Harris LLC lifted its stake in Bausch Health Companies by 948.6% in the second quarter. Sanders Morris Harris LLC now owns 110,100 shares of the company’s stock valued at $2,779,000 after buying an additional 99,600 shares during the period. Investors Research Corp lifted its stake in Bausch Health Companies by 85.7% in the second quarter. Investors Research Corp now owns 1,300 shares of the company’s stock valued at $33,000 after buying an additional 600 shares during the period. Amundi Pioneer Asset Management Inc. increased its holdings in shares of Bausch Health Companies by 123.0% during the first quarter. Amundi Pioneer Asset Management Inc. now owns 202,426 shares of the company’s stock valued at $5,000,000 after acquiring an additional 111,654 shares in the last quarter. Finally, FMR LLC increased its holdings in shares of Bausch Health Companies by 14.4% during the first quarter. FMR LLC now owns 312,264 shares of the company’s stock valued at $7,704,000 after acquiring an additional 39,276 shares in the last quarter. Institutional investors own 53.67% of the company’s stock.

About Bausch Health Companies

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.

Featured Article: What is the Dividend Aristocrat Index?

Analyst Recommendations for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.